Novo Nordisk (NVO) Thursday said it plans to significantly reduce the list price paid by US customers for its Tresiba and Fiasp insulin products starting January 2026.
The price of vials and pre-filled injector pens of the company's fast-acting Fiasp insulin will drop 75%, matching the price of its Novolog insulin, while the price of various dispensers of its long-acting Tresiba insulin analog will fall by 72.2%, making it 20% lower than its unbranded equivalent, insulin degludec, the Danish drugmaker said.
Novo Nordisk will cease production of its unbranded insulin biologicals by the end of 2025 and said it wanted to provide healthcare professionals, wholesalers and insurers with more than 12 months advance notice to ensure a smooth transition for patients.
Price: 108.87, Change: -0.10, Percent Change: -0.09
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。